A 2-Year, Prospective, Blinded-Rater, Open-Label, Active-Controlled, Multicenter, Randomized Study of Long-Term Efficacy and Effectiveness Comparing Risperdal Consta and Abilify (Aripiprazole) in Adults With Schizophrenia.

Trial Profile

A 2-Year, Prospective, Blinded-Rater, Open-Label, Active-Controlled, Multicenter, Randomized Study of Long-Term Efficacy and Effectiveness Comparing Risperdal Consta and Abilify (Aripiprazole) in Adults With Schizophrenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2011

At a glance

  • Drugs Aripiprazole; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 14 Jul 2009 Actual patient number (355) added as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Dec 2008 Planned number of patients changed from 316 to 357 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top